Teva Pharmaceutical Industries priced approximately $4.9 billion (equivalent) of senior notes across five euro- and dollar-denominated tranches maturing 2032-2037, with coupons ranging from 4.250% to 5.750%. Net proceeds plus cash on hand will fund conditional redemptions of existing notes carrying coupons of 6.750% to 8.125%, pay related fees, and support general corporate purposes. Settlement is expected on or about Sept. 16, 2026.
Five tranches of unsecured paper, split between euros and dollars, will settle on or about Sept. 16, 2026, and carry coupons of 4.250% to 5.750% — a step down from the 6.750% to 8.125% series Teva Pharmaceutical Industries Ltd. intends to retire.
The Israeli drugmaker said the settlement will satisfy the funding condition attached to the conditional redemptions. Teva issued the redemption notices on Sept. 8, 2026, and said it may add further notices or amend principal amounts at its sole discretion, though it is under no obligation to do so.
The offering splits into €1 billion of 4.250% notes due 2033 and €500 million of 4.625% notes due 2036, both issued through Teva Pharmaceutical Finance Netherlands II B.V.; $1 billion of 5.500% notes due 2034 and $1 billion of 5.750% notes due 2037 through Teva Pharmaceutical Finance Netherlands III B.V.; and $1.2 billion of 5.250% notes due 2032 through Teva Pharmaceutical Finance Netherlands IV B.V. The notes are unsecured senior obligations, guaranteed on a senior unsecured basis by Teva, and were sold under the company's automatic shelf registration statement filed with the SEC on Feb. 7, 2025.
On the redemption side, Teva intends to retire all outstanding 6.750% senior notes due 2028, all 7.875% sustainability-linked senior notes due 2029 and all 7.375% sustainability-linked senior notes due 2029. It also plans to redeem up to $450 million in principal of 4.750% sustainability-linked notes due 2027 and up to €1.25 billion of 4.375% sustainability-linked notes due 2030. On Sept. 10, Teva said it expects to issue an additional notice covering all of its 8.125% USD sustainability-linked senior notes due 2031, and a reduction notice trimming the 2030 euro redemption to €1.15 billion from €1.25 billion.
The arithmetic points to a lower interest burden. Every legacy series being retired in full carries a coupon above the highest rate on the new paper — 8.125%, 7.875%, 7.375% and 6.750% against a new-issue range of 4.250% to 5.750% — while the weighted average tenor extends into the 2030s. Net proceeds, together with cash on hand, will also cover fees and expenses, with any remainder available for general corporate purposes including repayment of debt at maturity, via tender offer or earlier redemption. Net proceeds may be temporarily invested before use.
The refinancing lands days after S&P Global Ratings upgraded Teva to BBB- on Sept. 4, 2026, moving the company to investment grade. Teva shares closed at $36.85 on Sept. 9, down 1.71% year to date but up 18.07% since Jan. 1, according to MarketScreener data. The stock carries a mean consensus rating of Buy from 13 analysts, with an average target price of $41.91, implying 13.73% upside.
For holders, the signal is a maturity extension at a materially lower coupon rather than a reduction in gross debt — the issuance adds roughly $4.9 billion of new obligations while retiring a comparable face amount, so leverage optics depend on how much of the redemption stack is completed. The next checkpoint is the Sept. 16 settlement, which must clear customary closing conditions before the conditional redemptions become effective; Teva's third-quarter results will show the first full-quarter interest expense under the new capital structure.
This article is for informational purposes only and does not constitute investment advice.
